Prevenar®- Conjugate Vaccine | Prevenar 13®

This site is intended only for healthcare professionals resident in India

Log Out

Our medicines

Therapy areas

Explore Content

Explore content

Events

Materials

Videos

Let's connect

Pfizer medical information

About

Burden of Disease

Description of the Disease

Indian Epidemiology

Pneumococcal Disease and Influenza

Challenges

Risk Factors

Secondary Infections

Mechanism of Action

Prevention of Pneumococcal Disease

Need for Pneumococcal Vaccination

In Elderly

In India

Cost-effectiveness of PCV13

Indian Studies

Global Studies

Legacy of Prevenar

Manufacturing

CRM₁₉₇

Activation and Conjugation

Pneumococcal Disease and Influenza

Distribution

Videos

Safety

Conclusion

Conclusion

Dosing

Dosing

Adults ≥18 Years of Age

Adults ≥50 Years of Age

COVID Vaccination

Flu Vaccination

Efficacy

Prevenar 13^® Clinical Experience

Introduction

Clinical Trials

Efficacy of Prevenar 13^®

Methodology

Criteria

Results

Conclusion

Effectiveness of Prevenar 13^®

Methodology

Analysis

Results

Limitations

Learnings

Conclusion

Indian Clinical Trials

Limitations

Conclusion

Recommendations for Use

Recommendations for Use

ACIP 2019

NCCN 2020

RSSDI 2020

IMA Guidelines

IAOH Guidelines for Working Adults

Clinical Practice Guidelines 2019 (ICS/NCCP)

The Geriatric Society of India, 2015

Indian Society of Nephrology

FAQs

PCV13 in Pulmonology

Role

Complications

Clinical Data

Recommendations

PCV13 in Nephrology

PCV13 in Oncology

Clinical Data

PCV13 in Rheumatology

Complications

Data

Recommendations

Consensus

PCV13 in Diabetes

Data

Recommendations

PCV13 in HIV Infection

Burden

Pulmonary Infection

Data

Efficacy

Recommendations

PCV13 in Cardiology

Burden

Data

Recommendations

Resources

Resources

Summary of Prescribing Information

Downloadable Resources

Explore Events

Explore Videos

Explore Materials

Conjugate Vaccine

A conjugate vaccine binds to polysaccharide-specific B-cells that communicate carrier protein antigens to T-cells, inducing a T-cell–dependent immune response. These T-cells release cytokines that help B-cells transform into plasma cells that immediately release antibodies and form memory B-cells that are responsible for immune memory (See figure below).^1-3

Immune memory is critical for long-lasting prevention of diseases. Upon first exposure to a T-cell–dependent antigen (i.e. protein), the immune system mounts a slow primary response and induces the formation of long-lived memory cells. Upon subsequent exposure, these memory cells launch a faster, stronger, and longer-lasting secondary response.^1-3

CRM₁₉₇, cross-reacting material; IgG, immunoglobulin G.

References:

Orenstein W, Offit P, Edwards KM, Plotkin S. Vaccine immunology. In: Siegrist CA, ed. Plotkin’s Vaccines. Elsevier Inc.; 2008:17-36. Accessed May 17, 2022. https://www.vacunashnrg.com.ar/archivosInteres/Elsevier_Vaccine_immunology.pdf

Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213-220.

Clutterbuck EA, Lazarus R, Yu L-M, Haber M, May L, Klugman K. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205(9):1408-1416.

Simonsen L, Taylor R, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2:1–10.

Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179–1186.

Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis. 2008;47:1328–1338.

Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

PP-PRV-IND-0661 July 2023

Prevention of Pneumococcal Disease

Dosing

Help protect your adult patients against pneumococcal pneumonia with single-dose administration

Learn more

Efficacy

Efficacy proven by the CAPiTA study

Learn more

Recommendations for Use

The ACIP recommends routine use of PCV13 among adults

Learn more

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Account

Sign Out

These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.

Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.

PP-PRV-IND-0661

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Button

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein

You are now leaving PfizerPro website

You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-DOL-IND-0251 18 JAN 2023